Epirium Bio Presented Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data for MF-300, Supporting its Role in Muscle Health, as a Late-Breaker at the Gerontological Society of America Annual Scientific Meeting 2025
Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, presented Phase 1 data for its lead candidate, MF-300, at the Gerontological Society of America’s (GSA) annual meeting held November 12-15, 2025, in Boston, MA.
Epirium Bio Announces Positive Phase 1 Clinical Trial Results Evaluating MF-300 in Healthy Volunteers, A First-In-Class, Oral 15-PGDH Enzyme Inhibitor, For the Treatment of Sarcopenia
Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced positive results from its Phase 1 trial evaluating MF-300, a novel therapy in development for sarcopenia. The primary endpoint of safety was achieved, and all doses of MF-300 studied were generally well tolerated with no subject discontinuations. MF-300 produced dose-related pharmacodynamic (PD) responses which were observed early and sustained over time, whereas placebo showed no meaningful changes, supporting target engagement and biologic activity. Pharmacokinetic (PK) analyses demonstrated dose-related increases in exposure, and the observed half-life supports convenient once-daily oral dosing.
Epirium Bio to Present MF-300 Preclinical Data at the International Conference on Frailty and Sarcopenia Research
Epirium Bio Inc. (Epirium), a clinical stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced the upcoming presentation of two scientific posters featuring preclinical data on MF-300 at the International Conference on Frailty and Sarcopenia Research (ICFSR), taking place March 12-14, 2025, in Toulouse, France. These presentations highlight the beneficial effects of MF-300 on muscle function in mouse models of aging.
